Effects of Caryota mitis profilin-loaded PLGA nanoparticles in a murine model of allergic asthma
Effects of Caryota mitis profilin-loaded PLGA nanoparticles in a murine model of allergic asthma
复制标题
DOI：
10.2147/ijn.s51633
复制
发表时间：
2013-11
影响因子：
8
通讯作者：
Xiaojun Xiao;Xiaowei Zeng;Xinxin Zhang;Li Ma;Xiaoyu Liu;Haiqiong Yu;Lin Mei;Zhigang Liu
中科院分区：
文献类型：
--
作者：
Xiaojun Xiao;Xiaowei Zeng;Xinxin Zhang;Li Ma;Xiaoyu Liu;Haiqiong Yu;Lin Mei;Zhigang Liu
背景花粉过敏是最常见的过敏性疾病。然而，热带花粉，如棕榈科的花粉，很少被调查与特定的免疫治疗研究高过敏性桦树，橄榄，豚草花粉。聚乳酸-羟基乙酸共聚物（PLGA）作为一种生物可降解聚合物在医疗器械中得到了广泛的应用，但作为疫苗佐剂用于预防和治疗过敏性疾病的研究却很少。在这项研究中，我们研究了重组Caryota mitis profilin（rCmP）负载PLGA纳米粒的免疫抑制作用及其相关机制。方法建立过敏性哮喘小鼠模型，以负载rCmP的PLGA纳米粒为佐剂进行特异性免疫治疗。通过测定气道高反应性和血清特异性抗体（IgE、IgG和IgG 2a）和细胞因子水平以及观察肺组织的组织学切片来评估该模型。结果载rCmP的PLGA纳米粒能有效抑制特异性IgE的产生和Th 2型细胞因子IL-4的分泌，促进特异性IgG 2a的产生和Th 1型细胞因子IFN-γ的分泌，使Th 2型应答转变为Th 1型应答，明显减轻过敏症状。结论PLGA比Al（OH）3更适合作为过敏原疫苗的特异性免疫佐剂，具有上级效力、更长的效力和更少的副作用。本文开发的负载rCmP的PLGA纳米颗粒为过敏性哮喘的特异性免疫治疗提供了一种有前途的途径。
Background Pollen allergy is the most common allergic disease. However, tropical pollens, such as those of Palmae, have seldom been investigated compared with the specific immunotherapy studies done on hyperallergenic birch, olive, and ragweed pollens. Although poly(lactic-co-glycolic acid) (PLGA) has been extensively applied as a biodegradable polymer in medical devices, it has rarely been utilized as a vaccine adjuvant to prevent and treat allergic disease. In this study, we investigated the immunotherapeutic effects of recombinant Caryota mitis profilin (rCmP)-loaded PLGA nanoparticles and the underlying mechanisms involved. Methods A mouse model of allergenic asthma was established for specific immunotherapy using rCmP-loaded PLGA nanoparticles as the adjuvant. The model was evaluated by determining airway hyperresponsiveness and levels of serum-specific antibodies (IgE, IgG, and IgG2a) and cytokines, and observing histologic sections of lung tissue. Results The rCmP-loaded PLGA nanoparticles effectively inhibited generation of specific IgE and secretion of the Th2 cytokine interleukin-4, facilitated generation of specific IgG2a and secretion of the Th1 cytokine interferon-gamma, converted the Th2 response to Th1, and evidently alleviated allergic symptoms. Conclusion PLGA functions more appropriately as a specific immunotherapy adjuvant for allergen vaccines than does conventional Al(OH)3 due to its superior efficacy, longer potency, and markedly fewer side effects. The rCmP-loaded PLGA nanoparticles developed herein offer a promising avenue for specific immunotherapy in allergic asthma.